Donald Henri Linszen - Publications

Affiliations: 
University of Amsterdam, Amsterdam, Netherlands 
Area:
psychiatry, psychopathology

153 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Lee SH, Byrne EM, Hultman CM, Kähler A, Vinkhuyzen AA, Ripke S, Andreassen OA, Frisell T, Gusev A, Hu X, Karlsson R, Mantzioris VX, McGrath JJ, Mehta D, Stahl EA, ... ... Linszen DH, et al. New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology. PMID 26286434 DOI: 10.1093/ije/dyv136  0.52
2015 Maat A, van Montfort SJ, de Nijs J, Derks EM, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I. Emotion processing in schizophrenia is state and trait dependent. Schizophrenia Research. 161: 392-8. PMID 25543332 DOI: 10.1016/j.schres.2014.11.027  0.52
2015 van Tricht MJ, Bour LJ, Koelman JH, Derks EM, Braff DL, de Wilde OM, Boerée T, Linszen DH, de Haan L, Nieman DH. Qualitative and quantitative aspects of information processing in first psychosis: latent class analyses in patients, at-risk subjects, and controls. Psychophysiology. 52: 585-93. PMID 25376718 DOI: 10.1111/psyp.12379  0.52
2015 Ising HK, Smit F, Veling W, Rietdijk J, Dragt S, Klaassen RM, Savelsberg NS, Boonstra N, Nieman DH, Linszen DH, Wunderink L, van der Gaag M. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. Psychological Medicine. 45: 1435-46. PMID 25330734 DOI: 10.1017/S0033291714002530  0.52
2015 van Tricht MJ, Nieman DH, Koelman JT, Mensink AJ, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, de Haan L. Sensory gating in subjects at ultra high risk for developing a psychosis before and after a first psychotic episode. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 16: 12-21. PMID 22730901 DOI: 10.3109/15622975.2012.680911  0.52
2014 Quee PJ, Meijer JH, Islam MA, Aleman A, Alizadeh BZ, Meijer CJ, van den Heuvel ER. Premorbid adjustment profiles in psychosis and the role of familial factors. Journal of Abnormal Psychology. 123: 578-87. PMID 25000154 DOI: 10.1037/a0037189  0.52
2014 De Koning MB, Bloemen OJ, Van Duin ED, Booij J, Abel KM, De Haan L, Linszen DH, Van Amelsvoort TA. Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. Journal of Psychopharmacology (Oxford, England). 28: 553-560. PMID 24526133 DOI: 10.1177/0269881113519507  0.52
2014 van Tricht MJ, Ruhrmann S, Arns M, Müller R, Bodatsch M, Velthorst E, Koelman JH, Bour LJ, Zurek K, Schultze-Lutter F, Klosterkötter J, Linszen DH, de Haan L, Brockhaus-Dumke A, Nieman DH. Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. Schizophrenia Research. 153: 42-7. PMID 24508483 DOI: 10.1016/j.schres.2014.01.019  0.52
2014 Nieman DH, Ruhrmann S, Dragt S, Soen F, van Tricht MJ, Koelman JH, Bour LJ, Velthorst E, Becker HE, Weiser M, Linszen DH, de Haan L. Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. Schizophrenia Bulletin. 40: 1482-90. PMID 24142369 DOI: 10.1093/schbul/sbt145  0.52
2014 Rietdijk J, Fokkema M, Stahl D, Valmaggia L, Ising HK, Dragt S, Klaassen RM, Nieman DH, Loewy R, Cuijpers P, Delespaul P, Linszen DH, van der Gaag M. The distribution of self-reported psychotic-like experiences in non-psychotic help-seeking mental health patients in the general population; a factor mixture analysis. Social Psychiatry and Psychiatric Epidemiology. 49: 349-58. PMID 24126556 DOI: 10.1007/s00127-013-0772-1  0.52
2014 Quee PJ, Alizadeh BZ, Aleman A, van den Heuvel ER. Cognitive subtypes in non-affected siblings of schizophrenia patients: characteristics and profile congruency with affected family members. Psychological Medicine. 44: 395-405. PMID 23659373 DOI: 10.1017/S0033291713000809  0.52
2014 Lataster T, Verweij K, Viechtbauer W, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I. Effect of illness expression and liability on familial associations of clinical and subclinical psychosis phenotypes Acta Psychiatrica Scandinavica. 129: 44-53. PMID 23465170 DOI: 10.1111/acps.12102  0.52
2013 Degenhardt F, Priebe L, Meier S, Lennertz L, Streit F, Witt SH, Hofmann A, Becker T, Mössner R, Maier W, Nenadic I, Sauer H, Mattheisen M, Buizer-Voskamp J, Ophoff RA, et al. Duplications in RB1CC1 are associated with schizophrenia; identification in large European sample sets. Translational Psychiatry. 3: e326. PMID 26151896 DOI: 10.1038/tp.2013.101  0.52
2013 Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophrenia Bulletin. 39: 1242-51. PMID 24072808 DOI: 10.1093/schbul/sbt138  0.52
2013 van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, McGorry P, Cuijpers P. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophrenia Research. 149: 56-62. PMID 23870806 DOI: 10.1016/j.schres.2013.07.004  0.52
2013 van Tricht MJ, Harmsen EC, Koelman JH, Bour LJ, van Amelsvoort TA, Linszen DH, de Haan L, Nieman DH. Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 88: 149-56. PMID 23541998 DOI: 10.1016/j.ijpsycho.2013.03.012  0.52
2013 Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. Journal of Psychiatric Research. 47: 718-25. PMID 23472837 DOI: 10.1016/j.jpsychires.2013.01.024  0.52
2013 van den Berg SM, Paap MC, Derks EM. Using multidimensional modeling to combine self-report symptoms with clinical judgment of schizotypy. Psychiatry Research. 206: 75-80. PMID 23021911 DOI: 10.1016/j.psychres.2012.09.015  0.52
2013 Nieman DH, Velthorst E, Becker HE, de Haan L, Dingemans PM, Linszen DH, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, Morrison A, Schultze-Lutter F, et al. The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis. Acta Psychiatrica Scandinavica. 127: 53-61. PMID 22775300 DOI: 10.1111/j.1600-0447.2012.01899.x  0.52
2013 Bloemen OJ, de Koning MB, Gleich T, Meijer J, de Haan L, Linszen DH, Booij J, van Amelsvoort TA. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 126-32. PMID 22591910 DOI: 10.1016/j.euroneuro.2012.04.015  0.52
2013 de Haan L, Sterk B, Wouters L, Linszen DH. The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophrenia Bulletin. 39: 151-60. PMID 21799212 DOI: 10.1093/schbul/sbr077  0.52
2012 Scheltema Beduin AA, Swets M, Machielsen M, Korver N, Kahn RS, Linszen DH, Van Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I. Obsessive-compulsive symptoms in patients with schizophrenia: A naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients Journal of Clinical Psychiatry. 73: 1395-1402. PMID 23218156 DOI: 10.4088/JCP.11m07164  0.52
2012 Dekker N, Koeter M, Van Den Brink W. Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale. International Journal of Methods in Psychiatric Research. 21: 286-300. PMID 22961922 DOI: 10.1002/mpr.1362  0.52
2012 de Koning MB, Boot E, Bloemen OJ, van Duin ED, Abel KM, de Haan L, Linszen DH, van Amelsvoort TA. Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val(158) Met polymorphism in adults with 22q11 deletion syndrome. Journal of Psychopharmacology (Oxford, England). 26: 1548-60. PMID 22952320 DOI: 10.1177/0269881112456610  0.52
2012 van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RM, Koeter M, Cuijpers P, Wunderink L, Linszen DH. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophrenia Bulletin. 38: 1180-8. PMID 22941746 DOI: 10.1093/schbul/sbs105  0.52
2012 Ising HK, Veling W, Loewy RL, Rietveld MW, Rietdijk J, Dragt S, Klaassen RM, Nieman DH, Wunderink L, Linszen DH, van der Gaag M. The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. Schizophrenia Bulletin. 38: 1288-96. PMID 22516147 DOI: 10.1093/schbul/sbs068  0.52
2012 Velthorst E, Meijer C, Kahn RS, Linszen DH, vanOs J, Wiersm D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I. The association between social anhedonia, withdrawal and psychotic experiences in general and high-risk populations Schizophrenia Research. 138: 290-294. PMID 22484023 DOI: 10.1016/j.schres.2012.03.022  0.52
2012 Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychological Medicine. 42: 1903-11. PMID 22452790 DOI: 10.1017/S0033291712000062  0.52
2012 Korver N, Quee PJ, Boos HBM, Simons CJP, De Haan L, Kahn RS, Linszen DH. Genetic Risk and Outcome of Psychosis (GROUP), A multi site longitudinal cohort study focused on gene-environment interaction: Objectives, sample characteristics, recruitment and assessment methods International Journal of Methods in Psychiatric Research. 21: 205-221. PMID 22419500 DOI: 10.1002/mpr.1352  0.52
2012 Derks E, Cahn W, Kahn RS, Linszen DH, Van Os J, Wiersma D, Bruggeman R, De Haan L, Krabbendam L, Myin-Germeys I, Maat A, Fett AK. Social cognition and quality of life in schizophrenia Schizophrenia Research. 137: 212-218. PMID 22406280 DOI: 10.1016/j.schres.2012.02.017  0.52
2012 Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh BZ, Snieder H, Kahn RS, Linszen DH, Os Jv, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I. Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes European Neuropsychopharmacology. 22: 625-631. PMID 22386772 DOI: 10.1016/j.euroneuro.2012.01.006  0.52
2012 Meijer J, Simons CJP, Quee PJ, Verweij K, Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R. Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents Acta Psychiatrica Scandinavica. 125: 66-76. PMID 22013907 DOI: 10.1111/j.1600-0447.2011.01777.x  0.52
2012 Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, ... ... Linszen DH, et al. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatrica Scandinavica. 125: 45-53. PMID 21883099 DOI: 10.1111/j.1600-0447.2011.01763.x  0.52
2012 Velthorst E, Nieman DH, Veling W, Klaassen RM, Dragt S, Rietdijk J, Ising H, Wunderink L, Linszen DH, de Haan L, van der Gaag M. Ethnicity and baseline symptomatology in patients with an At Risk Mental State for psychosis. Psychological Medicine. 42: 247-56. PMID 21835093 DOI: 10.1017/S0033291711001486  0.52
2012 Machielsen M, Beduin AS, Dekker N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. Journal of Psychopharmacology (Oxford, England). 26: 189-95. PMID 21768161 DOI: 10.1177/0269881111408957  0.52
2012 Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade. European Psychiatry : the Journal of the Association of European Psychiatrists. 27: 9-18. PMID 21561742 DOI: 10.1016/j.eurpsy.2011.02.005  0.52
2011 Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ, Kahn RS, Linszen DH, Van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R. The validity of the DSM-IV diagnostic classification system of non-affective psychoses Australian and New Zealand Journal of Psychiatry. 45: 1061-1068. PMID 22026404 DOI: 10.3109/00048674.2011.620562  0.52
2011 Rietdijk J, Hogerzeil SJ, van Hemert AM, Cuijpers P, Linszen DH, van der Gaag M. Pathways to psychosis: help-seeking behavior in the prodromal phase. Schizophrenia Research. 132: 213-9. PMID 21907547 DOI: 10.1016/j.schres.2011.08.009  0.52
2011 Klaassen RM, Velthorst E, Nieman DH, de Haan L, Becker HE, Dingemans PM, van de Fliert JR, van der Gaag M, Linszen DH. Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms. Psychopathology. 44: 379-85. PMID 21847005 DOI: 10.1159/000325169  0.52
2011 Meijer JH, Schmitz N, Nieman DH, Becker HE, van Amelsvoort TA, Dingemans PM, Linszen DH, de Haan L. Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. Psychiatry Research. 194: 1-6. PMID 21831606 DOI: 10.1016/j.pscychresns.2011.01.004  0.52
2011 van Tricht MJ, Nieman DH, Koelman JH, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, de Haan L. Auditory ERP components before and after transition to a first psychotic episode. Biological Psychology. 87: 350-7. PMID 21536095 DOI: 10.1016/j.biopsycho.2011.04.005  0.52
2011 Bloemen OJ, Gleich T, de Koning MB, da Silva Alvis F, de Haan L, Linszen DH, Booij J, van Amelsvoort TA. Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biological Psychiatry. 70: e1-2; author reply e. PMID 21481842 DOI: 10.1016/j.biopsych.2010.11.030  0.52
2011 Boot E, Booij J, Zinkstok JR, Baas F, Swillen A, Owen MJ, Murphy DG, Murphy KC, Linszen DH, Van Amelsvoort TA. COMT Val(158) met genotype and striatal D(2/3) receptor binding in adults with 22q11 deletion syndrome. Synapse (New York, N.Y.). 65: 967-70. PMID 21465565 DOI: 10.1002/syn.20932  0.52
2011 Boot E, Booij J, Abeling N, Meijer J, da Silva Alves F, Zinkstok J, Baas F, Linszen D, van Amelsvoort T. Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val¹⁰⁸/¹⁵⁸Met polymorphism, gender and symptomatology. Journal of Psychopharmacology (Oxford, England). 25: 888-95. PMID 21447540 DOI: 10.1177/0269881111400644  0.52
2011 Sterk B, Lankreijer K, Linszen DH, de Haan L. Obsessive-compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms. The Australian and New Zealand Journal of Psychiatry. 45: 400-6. PMID 21087087 DOI: 10.3109/00048674.2010.533363  0.52
2011 Van Winkel R, Kahn RS, Linszen DH, Van Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up Archives of General Psychiatry. 68: 148-157. PMID 21041608 DOI: 10.1001/archgenpsychiatry.2010.152  0.52
2011 Kahn RS, Linszen DH, Van Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I. Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: An analysis of patient-sibling and sibling-control pairs Archives of General Psychiatry. 68: 138-147. PMID 20921112 DOI: 10.1001/archgenpsychiatry.2010.132  0.52
2011 Dragt S, Nieman DH, Veltman D, Becker HE, van de Fliert R, de Haan L, Linszen DH. Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophrenia Research. 125: 69-76. PMID 20884179 DOI: 10.1016/j.schres.2010.09.007  0.52
2011 Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, van den Oord E, Sullivan PF, Shi J, Levinson DF, Gejman PV, Sanders A, Duan J, Owen MJ, et al. GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Molecular Psychiatry. 16: 1117-29. PMID 20838396 DOI: 10.1038/mp.2010.96  0.52
2011 Velthorst E, Nieman DH, Klaassen RM, Becker HE, Dingemans PM, Linszen DH, De Haan L. Three-year course of clinical symptomatology in young people at ultra high risk for transition to psychosis. Acta Psychiatrica Scandinavica. 123: 36-42. PMID 20712825 DOI: 10.1111/j.1600-0447.2010.01593.x  0.52
2011 Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L. Reply to Fan and Hart Psychiatry Research - Neuroimaging. 191: 85. DOI: 10.1016/j.pscychresns.2010.08.009  0.52
2010 Velthorst E, Nieman DH, Linszen D, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, French P, Stevens H, et al. Disability in people clinically at high risk of psychosis. The British Journal of Psychiatry : the Journal of Mental Science. 197: 278-84. PMID 20884950 DOI: 10.1192/bjp.bp.109.075036  0.36
2010 van Nimwegen-Campailla L, van Beveren N, Laan W, van den Brink W, Linszen D, de Haan L. Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis. Pharmacopsychiatry. 43: 281. PMID 20839158 DOI: 10.1055/s-0030-1263172  0.32
2010 Sterk B, Slief EM, Blankers M, Linszen DH, de Haan L. Duration of untreated psychosis and ethnicity. Schizophrenia Research. 124: 238-9. PMID 20724112 DOI: 10.1016/j.schres.2010.07.024  0.52
2010 van Tricht MJ, Nieman DH, Koelman JH, van der Meer JN, Bour LJ, de Haan L, Linszen DH. Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biological Psychiatry. 68: 642-8. PMID 20627236 DOI: 10.1016/j.biopsych.2010.04.022  0.52
2010 van Tricht MJ, Nieman DH, Bour LJ, Boerée T, Koelman JH, de Haan L, Linszen DH. Increased saccadic rate during smooth pursuit eye movements in patients at Ultra High Risk for developing a psychosis. Brain and Cognition. 73: 215-21. PMID 20538400 DOI: 10.1016/j.bandc.2010.05.005  0.52
2010 Boerma MA, van der Stel JC, van Amelsvoort T, Linszen DH, de Haan L. [Women, schizophrenia and oestrogen; neurobiological hypotheses and hormonetherapy studies]. Tijdschrift Voor Psychiatrie. 52: 235-44. PMID 20503164  0.52
2010 Talamini LM, de Haan L, Nieman DH, Linszen DH, Meeter M. Reduced context effects on retrieval in first-episode schizophrenia. Plos One. 5: e10356. PMID 20436915 DOI: 10.1371/journal.pone.0010356  0.52
2010 Dragt S, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, de Haan L, van Amelsvoort TA, Linszen DH. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 55: 165-71. PMID 20370967  0.52
2010 Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, Spiering M, Schmitz N, Linszen DH. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. The Australian and New Zealand Journal of Psychiatry. 44: 230-6. PMID 20180725 DOI: 10.3109/00048670903487118  0.52
2010 Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, de Haan L, van Amelsvoort TA, Linszen DH. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? Psychological Medicine. 40: 1599-606. PMID 20132582 DOI: 10.1017/S0033291710000048  0.52
2010 Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, De Haan L, Linszen DH. Verbal fluency as a possible predictor for psychosis. European Psychiatry : the Journal of the Association of European Psychiatrists. 25: 105-10. PMID 20005685 DOI: 10.1016/j.eurpsy.2009.08.003  0.52
2010 Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Research. 181: 51-6. PMID 19962862 DOI: 10.1016/j.pscychresns.2009.06.003  0.52
2010 Peters BD, Dingemans PM, Dekker N, Blaas J, Akkerman E, van Amelsvoort TA, Majoie CB, den Heeten GJ, Linszen DH, de Haan L. White matter connectivity and psychosis in ultra-high-risk subjects: a diffusion tensor fiber tracking study. Psychiatry Research. 181: 44-50. PMID 19954931 DOI: 10.1016/j.pscychresns.2009.10.008  0.52
2010 Dekker N, Smeerdijk AM, Wiers RW, Duits JH, van Gelder G, Houben K, Schippers G, Linszen DH, de Haan L. Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls. Psychological Medicine. 40: 1325-36. PMID 19917142 DOI: 10.1017/S0033291709991814  0.52
2010 Bloemen OJ, de Koning MB, Schmitz N, Nieman DH, Becker HE, de Haan L, Dingemans P, Linszen DH, van Amelsvoort TA. White-matter markers for psychosis in a prospective ultra-high-risk cohort. Psychological Medicine. 40: 1297-304. PMID 19895720 DOI: 10.1017/S0033291709991711  0.52
2010 Boot E, Booij J, Zinkstok JR, de Haan L, Linszen DH, Baas F, van Amelsvoort TA. Striatal Dâ‚‚ receptor binding in 22q11 deletion syndrome: an [¹²³I]IBZM SPECT study. Journal of Psychopharmacology (Oxford, England). 24: 1525-31. PMID 19406852 DOI: 10.1177/0269881109104854  0.52
2009 Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, de Haan L. Subjective effects of cannabis before the first psychotic episode. The Australian and New Zealand Journal of Psychiatry. 43: 1155-62. PMID 20001415 DOI: 10.3109/00048670903179095  0.52
2009 Dekker N, Linszen DH, De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology. 42: 350-60. PMID 19752588 DOI: 10.1159/000236906  0.52
2009 Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? Psychopharmacology Bulletin. 42: 75-88. PMID 19629024  0.52
2009 Nieman DH, Rike WH, Becker HE, Dingemans PM, van Amelsvoort TA, de Haan L, van der Gaag M, Denys DA, Linszen DH. Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. International Clinical Psychopharmacology. 24: 223-8. PMID 19521246 DOI: 10.1097/YIC.0b013e32832e0a76  0.52
2009 Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, de Haan L. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 81: 61-3. PMID 19477108 DOI: 10.1016/j.plefa.2009.04.007  0.52
2009 de Koning MB, Bloemen OJ, van Amelsvoort TA, Becker HE, Nieman DH, van der Gaag M, Linszen DH. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatrica Scandinavica. 119: 426-42. PMID 19392813 DOI: 10.1111/j.1600-0447.2009.01372.x  0.52
2009 Peters BD, Schmitz N, Dingemans PM, van Amelsvoort TA, Linszen DH, de Haan L, Majoie CB, den Heeten GJ. Preliminary evidence for reduced frontal white matter integrity in subjects at ultra-high-risk for psychosis. Schizophrenia Research. 111: 192-3. PMID 19372031 DOI: 10.1016/j.schres.2009.03.018  0.52
2009 Velthorst E, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, Klaassen R, de Haan L, van Amelsvoort T, Linszen DH. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophrenia Research. 109: 60-5. PMID 19272756 DOI: 10.1016/j.schres.2009.02.002  0.52
2008 de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Boerée T, Linszen DH. P300 deficits are present in young first-episode patients with schizophrenia and not in their healthy young siblings. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 119: 2721-6. PMID 18986832 DOI: 10.1016/j.clinph.2008.08.024  0.52
2008 Peters BD, de Haan L, Dekker N, Blaas J, Becker HE, Dingemans PM, Akkerman EM, Majoie CB, van Amelsvoort T, den Heeten GJ, Linszen DH. White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis. Neuropsychobiology. 58: 19-28. PMID 18781087 DOI: 10.1159/000154476  0.52
2008 Stefansson H, Rujescu D, Cichon S, Pietiläinen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 455: 232-6. PMID 18668039 DOI: 10.1038/nature07229  0.52
2008 Boot E, Booij J, Hasler G, Zinkstok JR, de Haan L, Linszen DH, van Amelsvoort TA. AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. European Journal of Nuclear Medicine and Molecular Imaging. 35: 1350-6. PMID 18283451 DOI: 10.1007/s00259-008-0739-8  0.52
2008 van Amelsvoort T, Zinkstok J, Figee M, Daly E, Morris R, Owen MJ, Murphy KC, De Haan L, Linszen DH, Glaser B, Murphy DG. Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome. Psychological Medicine. 38: 89-100. PMID 17493297 DOI: 10.1017/S0033291707000700  0.52
2007 de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophrenia Research. 97: 137-51. PMID 17604606 DOI: 10.1016/j.schres.2007.04.028  0.52
2007 Zinkstok JR, de Wilde O, van Amelsvoort TA, Tanck MW, Baas F, Linszen DH. Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. Behavioral and Brain Functions : Bbf. 3: 19. PMID 17445278 DOI: 10.1186/1744-9081-3-19  0.52
2007 de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH. Failure to find P50 suppression deficits in young first-episode patients with schizophrenia and clinically unaffected siblings. Schizophrenia Bulletin. 33: 1319-23. PMID 17289652 DOI: 10.1093/schbul/sbm001  0.52
2006 de Haan L, Hoogeboom B, Beuk N, Wouters L, Dingemans PM, Linszen DH. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacology Bulletin. 39: 25-30. PMID 17065972  0.52
2006 Weeda MR, Peters BD, De Haan L, Linszen DH. [Residual neuropsychological, structural and functional brain abnormalities after long-term cannabis use]. Tijdschrift Voor Psychiatrie. 48: 185-93. PMID 16956082  0.52
2006 Klaassen MC, Nieman DH, Becker HE, Linszen DH. [Is there any point in detecting high risk factors prior to a first psychosis?]. Tijdschrift Voor Psychiatrie. 48: 467-76. PMID 16956006  0.52
2006 Barkhof E, de Haan L, Meijer CJ, Fouwels AJ, Keet IPM, Hulstijn KP, Schippers GM, Linszen DH. Motivational interviewing in psychotic disorders Current Psychiatry Reviews. 2: 207-213. DOI: 10.2174/157340006776875932  0.52
2006 Storosum JG, Wohlfarth T, Gispen-De Wied CC, Linszen DH, Gersons BPR, Van Zwieten BJ, Van Den Brink WIM. Dr. Storosum and colleagues reply [8] American Journal of Psychiatry. 163: 329.  0.52
2005 Lenior ME, Dingemans PM, Schene AH, Linszen DH. Predictors of the early 5-year course of schizophrenia: a path analysis. Schizophrenia Bulletin. 31: 781-91. PMID 16123531 DOI: 10.1093/schbul/sbi010  0.52
2005 Storosum JG, Wohlfarth T, Gispen-de Wied CC, Linszen DH, Gersons BP, van Zwieten BJ, van den Brink W. Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. The American Journal of Psychiatry. 162: 799-802. PMID 15800158 DOI: 10.1176/appi.ajp.162.4.799  0.52
2004 Kho KH, Blansjaar BA, de Vries S, Babuskova D, Zwinderman AH, Linszen DH. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study. European Archives of Psychiatry and Clinical Neuroscience. 254: 372-9. PMID 15538604 DOI: 10.1007/s00406-004-0517-y  0.52
2004 Kho KH, Blansjaar BA, Vothknecht S, Cornelissen NM, Koomen E, Zwinderman AH, Linszen DH. A study into predictors for the speed of response to electroconvulsive therapy. The Journal of Ect. 20: 154-9. PMID 15342999 DOI: 10.1097/00124509-200409000-00006  0.52
2004 de Haan L, Welborn K, Krikke M, Linszen DH. Opinions of mothers on the first psychotic episode and the start of treatment of their child. European Psychiatry : the Journal of the Association of European Psychiatrists. 19: 226-9. PMID 15196605 DOI: 10.1016/j.eurpsy.2003.09.010  0.52
2004 de Haan L, van Amelsvoort T, Linszen DH. Elevated homocysteine levels in schizophrenia. The American Journal of Psychiatry. 161: 1131-2; author reply. PMID 15169714  0.52
2004 Figee M, Van Amelsvoort T, De Haan L, Linszen DH. Genetic research into schizophrenia. A review | Genetisch onderzoek bij schizofrenie. Een overzicht Tijdschrift Voor Psychiatrie. 46: 15-26.  0.52
2003 de Haan L, Linszen DH, Lenior ME, de Win ED, Gorsira R. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophrenia Bulletin. 29: 341-8. PMID 14552508  0.52
2003 Verhoeven WMA, Tuinier S, Vorstman JAS, Van Amelsvoort TAMJ, Güzelcan Y, De Haan L, De Ranitz AGS, Udink Ten Cate FEA, Van Schaik P, Kahn RS, Linszen DH, Beemer FA. Schizophrenia and the 22q11 deletion syndrome [1] | Schizofrenie en het 22q11-deletiesyndroom Nederlands Tijdschrift Voor Geneeskunde. 147: 317-318. PMID 12622010  0.52
2003 Lenior ME, Dingemans PMAJ, Schene AH, Linszen DH. Predictors and the five-year course of early-onset schizophrenia. A path analysis | Predictoren en het vijfjarig sociaal en symptomatisch beloop van recent ontstane schizofrenie: Een padanalyse Tijdschrift Voor Psychiatrie. 45: 597-608.  0.52
2003 Peters BD, De Haan L, Linszen DH. Impaired connectivity in schizophrenia: Abnormalities in brain white matter | Disconnectiviteit bij schizofrenie: Afwijkingen in de witte stof van de hersenen Tijdschrift Voor Psychiatrie. 45: 507-515.  0.52
2002 Güzelcan Y, van Amelsvoort T, de Haan L, van Schaik P, Linszen DH. [Schizophrenia and the 22q11 deletion syndrome]. Nederlands Tijdschrift Voor Geneeskunde. 146: 2019-21. PMID 12428460  0.52
2002 Lenior ME, Dingemans PM, Schene AH, Hart AA, Linszen DH. The course of parental expressed emotion and psychotic episodes after family intervention in recent-onset schizophrenia. A longitudinal study. Schizophrenia Research. 57: 183-90. PMID 12223249 DOI: 10.1016/S0920-9964(01)00305-X  0.52
2002 de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology. 162: 24-8. PMID 12107613 DOI: 10.1007/s00213-002-1054-x  0.52
2002 Wolthaus JE, Dingemans PM, Schene AH, Linszen DH, Wiersma D, Van Den Bosch RJ, Cahn W, Hijman R. Caregiver burden in recent-onset schizophrenia and spectrum disorders: the influence of symptoms and personality traits. The Journal of Nervous and Mental Disease. 190: 241-7. PMID 11960085 DOI: 10.1097/00005053-200204000-00005  0.52
2002 Nieman DH, Koelman JH, Linszen DH, Bour LJ, Dingemans PM, Ongerboer de Visser BW. Clinical and neuropsychological correlates of the P300 in schizophrenia. Schizophrenia Research. 55: 105-13. PMID 11955970 DOI: 10.1016/S0920-9964(01)00184-0  0.52
2002 Lavalaye J, De Haan L, Linszen DH. Dopamine receptor occupancy by antipsychotic medication, an overview of SPECT and PET research | Dopaminereceptorbezetting door antipsychotica: Een overzicht van SPECT- en PET-onderzoek Tijdschrift Voor Psychiatrie. 44: 39-44.  0.52
2001 Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology. 156: 53-7. PMID 11465633 DOI: 10.1007/s002130000679  0.52
2001 Lenior ME, Dingemans PM, Linszen DH, de Haan L, Schene AH. Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention. The British Journal of Psychiatry : the Journal of Mental Science. 179: 53-8. PMID 11435269  0.52
2001 Lavalaye J, Sarlet A, Booij J, Linszen DH, Reneman L, Gersons BP, van Royen EA. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology. 155: 107-9. PMID 11374328 DOI: 10.1007/s002130000670  0.52
2001 Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biological Psychiatry. 49: 510-22. PMID 11257236 DOI: 10.1016/S0006-3223(00)00986-0  0.52
2001 Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken JB, Gersons BP, van Royen EA. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophrenia Research. 47: 59-67. PMID 11163545 DOI: 10.1016/S0920-9964(00)00023-2  0.52
2001 De Haan L, Timmer T, Linszen DH, Lenior ME, Wouters L. The 5-year outcome of schizophrenia after a first admission, in the western world. A meta-analysis | Het beloop van schizofrenie gedurende vijfjaar na een eerste opname, in de westerse wereld. Een meta-analyse Tijdschrift Voor Psychiatrie. 43: 559-565.  0.52
2001 Van Bruggen JM, Linszen DH, Dingemans PMAJ, Gersons BPR. Weight gain and antipsychotic drugs | Gewichtstoename en antipsychotica Tijdschrift Voor Psychiatrie. 43: 95-104.  0.52
2001 De Haan L, Van Bruggen JM, Lavalaye J, Scholte WF, Wouters L, Storosum J, Linszen DH. Rehabilitation of conventional antipsychotics. An overview of meta-analyses | Rehabilitatie van klassieke antipsychotica: Een overzicht van meta-analyses Tijdschrift Voor Psychiatrie. 43: 259-264.  0.52
2001 Cohen D, Van Bruggen JM, Linszen DH, Dingemans PMAJ, Gersons BPR. Weight gain and antipsychotic drugs | Reactie op 'gewichtstoename en antipsychotica' Tijdschrift Voor Psychiatrie. 43: 733-735.  0.52
2001 Lenior ME, Dingemans PMAJ, Linszen DH, De Haan L, Schene AH. Social functioning and the course of recent-onset schizophrenia. A 5-year follow-up study | Sociaal functioneren en het beloop van recent ontstane schizofrenie. Een vervolgstudie over de eerste vijf jaar Tijdschrift Voor Psychiatrie. 43: 219-231.  0.52
2000 Wolthaus JE, Dingemans PM, Schene AH, Linszen DH, Knegtering H, Holthausen EA, Cahn W, Hijman R. Component structure of the positive and negative syndrome scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. Psychopharmacology. 150: 399-403. PMID 10958081 DOI: 10.1007/s002130000459  0.52
2000 Nieman DH, Bour LJ, Linszen DH, Goede J, Koelman JH, Gersons BP, Ongerboer de Visser BW. Neuropsychological and clinical correlates of antisaccade task performance in schizophrenia. Neurology. 54: 866-71. PMID 10690978  0.52
1999 Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Research. 92: 33-44. PMID 10688158 DOI: 10.1016/S0925-4927(99)00032-3  0.52
1999 de Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. The Journal of Clinical Psychiatry. 60: 364-5. PMID 10401913  0.52
1998 Linszen DH, Dingemans PM, Lenior ME, Scholte WF, de Haan L, Goldstein MJ. Early detection and intervention in schizophrenia. International Clinical Psychopharmacology. 13: S31-4. PMID 9690968 DOI: 10.1097/00004850-199804004-00006  0.52
1998 Linszen DH, Dingemans PM, Lenior ME, Scholte WF, Goldstein M. Early family and individual interventions and relapse in recent-onset schizophrenia and related disorders Italian Journal of Psychiatry and Behavioural Sciences. 8: 77-84.  0.52
1998 Dingemans PMAJ, Lenior ME, Linszen DH. Personality and schizophrenic relapse International Clinical Psychopharmacology. 13: S89-S95.  0.52
1998 Linszen DH, Dingemans PMAJ, Scholte WF, Lenior ME, Goldstein M. Early recognition, intensive intervention and other protective and risk factors for psychotic relapse in patients with first psychotic episodes in schizophrenia International Clinical Psychopharmacology. 13: S7-S12.  0.52
1998 Lenior ME, Linszen DH, Dingemans PMAJ. The association between parental expressed emotion and psychotic relapse: Applying a quantitative measure for expressed emotion International Clinical Psychopharmacology. 13: S81-S87.  0.52
1998 Lenior ME, Dingemans PMAJ, Linszen DH. Expressed emotion and psychotic relapse. Scalability of the items of the five minute speech sample | 'Expressed emotion' en psychoserecidief. Schaalbaarheid van items behorend tot het vijfminuteninterview Tijdschrift Voor Psychiatrie. 40: 14-26.  0.52
1998 Linszen DH, Lieberman JA, Verhoeff J. Introduction International Clinical Psychopharmacology. 13: S1.  0.52
1998 De Haan L, Linszen DH, Gorsira R. Early intervention, social functioning and psychotic relapse of patients with recent-onset schizophrenic disorders International Clinical Psychopharmacology. 13: S63-S66.  0.52
1998 Nieman DH, Ongerboer De Visser BW, Koelman JHTM, Hofman WF, Linszen DH. The P3 event-related potential in young recent-onset schizophrenic patients International Clinical Psychopharmacology. 13: S67-S73.  0.52
1997 Nugter MA, Dingemans PM, Linszen DH, Van der Does AJ, Gersons BP. The relationships between expressed emotion, affective style and communication deviance in recent-onset schizophrenia. Acta Psychiatrica Scandinavica. 96: 445-51. PMID 9421341  0.52
1997 Booij J, Korn P, Linszen DH, van Royen EA. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. European Journal of Nuclear Medicine. 24: 674-7. PMID 9169577 DOI: 10.1007/s002590050105  0.52
1997 Nugter MA, Dingemans PM, Linszen DH, Van der Does AJ, Gersons BP. Parental communication deviance: its stability and the effect of family treatment in recent-onset schizophrenia. Acta Psychiatrica Scandinavica. 95: 199-204. PMID 9111852  0.52
1997 Lenior ME, Dingemans PM, Linszen DH. A quantitative measure for expressed emotion. Psychiatry Research. 69: 53-65. PMID 9080545 DOI: 10.1016/S0165-1781(96)02951-4  0.52
1997 Linszen DH, Dingemans PM, Nugter MA, Van der Does AJ, Scholte WF, Lenior MA. Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophrenia Bulletin. 23: 119-30. PMID 9050118  0.52
1997 De Haan L, Linszen DH, Gorsira R. Early intervention, social functioning, psychotic relapse and suicide of patients with recent onset schizophrenia and other psychotic disorders | Vroegtijdige intensieve interventie, sociaal functioneren, psychoserecidief en suicide bij patienten met recent ontstane schizofrenie en verwante stoornissen Tijdschrift Voor Psychiatrie. 39: 24-36.  0.52
1996 Van der Does AJ, Dingemans PM, Linszen DH, Nugter MA, Scholte WF. Symptoms, cognitive and social functioning in recent-onset schizophrenia: a longitudinal study. Schizophrenia Research. 19: 61-71. PMID 9147497 DOI: 10.1016/0920-9964(95)00046-1  0.52
1996 Dingemans PM, Lenior ME, Linszen DH. Patient psychopathology and parental expressed emotion | Psychopathologie van patienten met schizofrenie en 'Expressed Emotion' van de ouders Tijdschrift Voor Psychiatrie. 38: 660-667.  0.52
1995 Dingemans PM, Linszen DH, Lenior ME, Smeets RM. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology. 122: 263-7. PMID 8748395 DOI: 10.1007/BF02246547  0.52
1995 Willem Van der Does AJ, Dingemans PM, Linszen DH, Nugter MA, Scholte WF. Dimensions and subtypes of recent-onset schizophrenia. A longitudinal analysis. The Journal of Nervous and Mental Disease. 183: 681-7. PMID 7595429  0.52
1995 Dingemans PMAJ, Linszen DH, Lenior ME, Smeets R. The dimensional structure of the Expanded Brief Psychiatry Rating Scale | DIMENSIONELE STRUCTUUR VAN DE KORTE PSYCHIATRISCHE BEOORDELINGSSCHAAL (BPRS-E) Tijdschrift Voor Psychiatrie. 37: 427-432.  0.52
1995 Linszen DH, Dingemans PM, Lenoir ME. Cannabis use and the course of reset/onset schizophrenic disorders | SAMENHANG TUSSEN GEBRUIK VAN CANNABIS EN RECIDIEF/EXACERBATIE VAN PSYCHOSE BIJ PATIENTEN MET SCHIZOFRENIE Nederlands Tijdschrift Voor Geneeskunde. 139: 502-507.  0.52
1995 Dingemans PMAJ, Linszen DH, Lenior ME. Personality and schizophrenia | PERSOONLIJKHEIDSSTOORNISSEN EN SCHIZOFRENIERECIDIVE Tijdschrift Voor Psychiatrie. 37: 312-328.  0.52
1994 Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry. 51: 273-9. PMID 8161287 DOI: 10.1001/archpsyc.1994.03950040017002  0.52
1994 Linszen DH, Dingemans PM, Lenior ME, Nugter MA, Scholte WF, Van der Does AJ. Relapse criteria in schizophrenic disorders: different perspectives. Psychiatry Research. 54: 273-81. PMID 7792331 DOI: 10.1016/0165-1781(94)90021-3  0.52
1994 Linszen DH, Dingemans PMAJ, Scholte WF, Lenior ME, Van Der Does AJW, Nugter MA. 'Expressed emotion (EE)' and patients attributes as risk factors for psychotic relapse in schizophrenic disorders | 'EXPRESSED EMOTION (EE)' EN PATIENTGEBONDEN KENMERKEN ALS RISICOFACTOREN VOOR PSYCHOSERECIDIEF BIJ SCHIZOFRENE STOORNISSEN Tijdschrift Voor Psychiatrie. 36: 495-508.  0.52
1993 Van der Does AJ, Linszen DH, Dingemans PM, Nugter MA, Scholte WF. A dimensional and categorical approach to the symptomatology of recent-onset schizophrenia. The Journal of Nervous and Mental Disease. 181: 744-9. PMID 8254326  0.52
1993 Van der Does AJ, Dingemans PM, Linszen DH, Nugter MA, Scholte WF. Symptom dimensions and cognitive and social functioning in recent-onset schizophrenia. Psychological Medicine. 23: 745-53. PMID 8234580  0.52
1993 Linszen DH, Dingemans PMAJ, Scholte WF, Van der Does JW, Nugter MA, Lenior ME. Treatment, Expressed Emotion an relapse in recent onset schizophrenia an related disorders | BEHANDELING, 'EXPRESSED EMOTION' EN PSYCHOSERECIDIEF BIJ RECENT ONTSTANE SCHIZOFRENE STOORNISSEN Tijdschrift Voor Psychiatrie. 35: 625-640.  0.52
1992 Sno HN, Linszen DH, de Jonghe F. Art imitates life: Déjà vu experiences in prose and poetry. The British Journal of Psychiatry : the Journal of Mental Science. 160: 511-8. PMID 1571751  0.52
1992 Sno HN, Linszen DH, de Jonghe F. Déjà vu experiences and reduplicative paramnesia. The British Journal of Psychiatry : the Journal of Mental Science. 161: 565-8. PMID 1393349  0.52
1992 Sno HN, Linszen DH, De Jonghe F. On deja vu experiences in belles-lettres | EEN ZONDERLINGE ZWEMING: OVER DEJA VU-ERVARINGEN IN DE BELLETTRIE Tijdschrift Voor Psychiatrie. 34: 243-254.  0.52
1991 Kafka JS, Sno HN, Linszen DH. Deja vu and synesthesia [11] American Journal of Psychiatry. 148: 951-952. PMID 2053646  0.52
1991 Kohn SR, Rosen DH, Pagliaro L, Fleminger S, Sno HN, Linszen DH. Deja vu phenomena [20] American Journal of Psychiatry. 148: 1417-1419. PMID 1772492  0.52
1990 Sno HN, Linszen DH. The déjà vu experience: remembrance of things past? The American Journal of Psychiatry. 147: 1587-95. PMID 2244635  0.52
Show low-probability matches.